FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to oxazolopyrimidine compounds of formula Iin any of its stereoisomer forms or its physiologically acceptable salt, wherein A is specified in NH, O and S； X is specified in (C-C)-alkanediyl, (C-C)-alkenediyl, and (C-C)-alkanediyloxy, wherein oxygen atom of (C-C)-alkanediyloxy group is related to the group R； Ris specified in hydrogen and (C-C)-alkyl； Ris specified in phenylene, which is optionally substituted in one or more carbon atoms in the ring by identical or different substitutes R； Ris specified in (C-C)-alkyl optionally substituted by 1-3 fluorine atoms, or Ris a residue of a saturated or unsaturated 5-merous - 10-merous monocyclic or bicyclic ring, which contains 0, 1 or 2 heteroatoms in the ring specified in N, O and S, and represents cyclopentyl, indanyl, phenyl, naphthyl, thiazole, isothiazole, pyridyl, benzothiazole or quinoline, and wherein a residue of the ring is optionally substituted in one or two carbon atoms in the ring by identical or different substitutes R； Ris specified in (C-C)-alkyl optionally substituted by 1-3 fluorine atoms； Ris specified in halogen, (C-C)-alkyl optionally substituted by 1-3 fluorine atoms, (C-C)-alkyloxy optionally substituted by 1-3 fluorine atoms, and (C-C)-alkyl-S(O)- optionally substituted by 1-3 fluorine atoms； m is equal to 0. The invention also refers to a pharmaceutical composition containing the compounds of formula I, and to a method for producing the compounds of formula I.EFFECT: producing the compounds of formula I applicable for EDG-1 receptor activation.14 cl, 2 tbl, 2 exИзобретение относится к оксазолопиримидиновым соединениям формулы I в любой из его стереоизомерных форм или его физиологически приемлемой соли, где А выбирают из NH, О и S； X выбирают из (C-С)-алкандиила, (С-С)-алкендиила, и (С-С)-алкандиилокси, где атом кислорода (C-C)-алкандиилокси-группы связан с группой R； Rвыбирают из водорода и (C-C)-алкила； Rвыбирают из фенилена, который не
